HEART FAILURE, DIABETES, BETA-BLOCKERS AND RISK OF HYPOGLYCEMIA
https://doi.org/10.20996/1819-6446-2008-4-3-47-51
Abstract
Aim. To evaluate an influence of carvedilol on risk of hypoglycemia in patients with diabetes type 2 (D2) and chronic heart failure (CHF) treated with angiotensin converting enzyme (ACE) inhibitors.
Material and methods. 13 patients (10 men, 3 women; aged 59,8±6,7 y.o.) with D2 and CHF caused by ischemic heart disease were included in the study. Before inclusion all patients were treated with ACE inhibitors and various beta-blockers (atenolol, metoprolol, bisoprolol). These beta-blockers were changed for carvedilol. Heart ultrasonography, blood pressure control, glycemia monitoring, HbA1c level determination were performed before, during and after carvedilol therapy.
Results. Carvedilol reduces frequency and duration of hypoglycaemia episodes. There were not episodes of severe hypoglycaemia during carvedilol therapy.
Conclusion. Carvedilol reduces risk of hypoglycemia when it is used in combination with ACE inhiditors in diabetic patients with CHF.
About the Authors
A. A. Aleksandrov
Endocrinology Research Center of Rosmedtechnology, Moscow
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
O. А. Shatskaya
Endocrinology Research Center of Rosmedtechnology, Moscow
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
S. S. Kuharenko
Endocrinology Research Center of Rosmedtechnology, Moscow
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
E. N. Drozdova
Endocrinology Research Center of Rosmedtechnology, Moscow
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
I. Z. Bondarenko
Endocrinology Research Center of Rosmedtechnology, Moscow
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
N. D. Tabidze
Endocrinology Research Center of Rosmedtechnology, Moscow
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
M. V. Shestakova
Endocrinology Research Center of Rosmedtechnology, Moscow
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
References
1. Rydn L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28(1):88-136.
2. McGill J.B., Bakris G.L., Fonseca V. et al. Beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab 2007;9(3):408-17.
3. Bakris G.L., Fonseca V., Katholi R.E. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292(18):2227-36.
4. Преображенский Д.В., Сидоренко Б.А, Дедова И.С., Тарыкина Е.В. Блокаторы β-адренорецепторов в лечении сердечно- сосудистых заболеваний: место карведилола. Кардиология 2006;(12):80-7.
5. Kendall M.J., Lynch K.P., Hjalmarson A., Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995;123(5):358-67.
6. Skinner J.E. Regulation of cardiac vulnerability by the cerebral defense system. J Am Coll Cardiol 1985;5(6 Suppl):88B-94B.
7. Townend J.N., Littler W.A. Cardiac vagal activity: a target for intervention in heart disease. Lancet 1995;345:937-8.
8. Delsperger K.C., Martins J.B., Clothier J.L., Marcus M.L. Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta blockade. Circulation 1990;82:941-50.
9. Parker G.W., Michael L.H., Hartley C.J., et al. Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res 1990;66:259-70.
10. Ablad B., Bjur T., Bjrkman J.A., Edstrm T. Prevention of ventricular fibrillation requires central beta-adrenoceptor blockade in rabbits. Scand Cardiovasc J 2007;41(4):221-9.
11. Hoffman R.P., Sinkey C.A., Dopp J.M., Phillips B.G. System and local adrenergic regulation of muscle glucose utilization during hypoglycemia in healthy subjects. Diabetes 2002;51:734-42.
Review
For citations:
Aleksandrov A.A., Shatskaya O.А., Kuharenko S.S., Drozdova E.N., Bondarenko I.Z., Tabidze N.D., Shestakova M.V. HEART FAILURE, DIABETES, BETA-BLOCKERS AND RISK OF HYPOGLYCEMIA. Rational Pharmacotherapy in Cardiology. 2008;4(3):47-51. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-3-47-51
Views:
1365
.jpg)
Email this article 